Senate legislation not only would impose a requirement for infant formula firms to report production disruptions to the US Food and Drug Administration, but also require the agency to expand its regulation of the formula space and establish an office focused on the market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?